Stockscreener 앱 받기
16.13
1.13%
0.18
시간 외 거래:
16.13
전일 마감가:
$15.95
열려 있는:
$16
하루 거래량:
10.32M
Relative Volume:
1.16
시가총액:
$18.58B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-5.0883
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+12.33%
1개월 성능:
+26.41%
6개월 성능:
+63.59%
1년 성능:
+52.03%
1일 변동 폭
$15.87
$16.18
1주일 범위
$14.10
$16.18
52주 변동 폭
$6.85
$16.18
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.13 | 18.37B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com South Africa
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Inc. stock rises Monday, outperforms market - MSN
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ) - Seeking Alpha
US drugmaker Viatris appoints in-house pharma veteran as next CLO - The Global Legal Post
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Viatris to Buy From Neutral, Adjusts Price Target to $18 From $11 - marketscreener.com
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Announces Chief Legal Officer Transition and Successor - The Globe and Mail
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris Appoints Matthew J. Maletta as Chief Legal Officer – Company Announcement - Financial Times
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $13.49 - Investing.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What Are Wall Street Analysts' Target Price for Viatris Stock? - Barchart.com
What Does the Market Think About Viatris Inc? - Benzinga
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com UK
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com Nigeria
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Viatris launches ‘EmpowerED for Life’ for men’s health in Africa - MSN
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
0.15%
자본화:
|
볼륨(24시간):